EyenoviaEYEN
About: Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Employees: 57
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3% less capital invested
Capital invested by funds: $7M [Q2] → $6.78M (-$213K) [Q3]
4.78% less ownership
Funds ownership: 21.86% [Q2] → 17.08% (-4.78%) [Q3]
22% less funds holding
Funds holding: 59 [Q2] → 46 (-13) [Q3]
36% less call options, than puts
Call options by funds: $7K | Put options by funds: $11K
63% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 19
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Matthew Caufield 28% 1-year accuracy 13 / 46 met price target | 1,702%upside $2 | Neutral Downgraded | 18 Nov 2024 |
HC Wainwright & Co. Matthew Caufield 28% 1-year accuracy 13 / 46 met price target | 10,711%upside $12 | Buy Reiterated | 13 Nov 2024 |
Financial journalist opinion
Based on 7 articles about EYEN published over the past 30 days
